MCID: SPR098
MIFTS: 58

Supranuclear Palsy, Progressive malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Blood diseases

Aliases & Classifications for Supranuclear Palsy, Progressive

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 36MedGen, 37MedlinePlus, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 48NINDS, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Supranuclear Palsy, Progressive:

Name: Supranuclear Palsy, Progressive 51 47 25 12 38
Progressive Supranuclear Palsy 11 47 25 48 53 37 13 67
Steele-Richardson-Olszewski Syndrome 11 47 25 48 69
Progressive Supranuclear Ophthalmoplegia 11 25 26
Psp 47 25 69
Familial Progressive Supranuclear Palsy 47 67
 
Progressive Supranuclear Palsy 1 69
Supranuclear Palsy Progressive 49
Richardson's Syndrome 25
Psp Syndrome 53
Psnp1 69

Characteristics:

Orphanet epidemiological data:

53
progressive supranuclear palsy:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (United States),1-9/100000 (Italy),1-5/10000 (Guadeloupe),1-9/100000 (United Kingdom),1-9/1000000 (Libyan Arab Jamahiriya),1-9/1000000 (United States),1-9/1000000 (Australia); Age of onset: Adult; Age of death: elderly

HPO:

63
supranuclear palsy, progressive:
Inheritance: autosomal dominant inheritance
Onset and clinical course: adult onset

Classifications:



External Ids:

OMIM51 601104
Disease Ontology11 DOID:678
ICD1029 G23.1
MeSH38 D013494
NCIt44 C85028
Orphanet53 ORPHA683
ICD10 via Orphanet30 G23.1
MESH via Orphanet39 D013494
UMLS via Orphanet68 C0038868
MedGen36 C0038868

Summaries for Supranuclear Palsy, Progressive

About this section
OMIM:51 Progressive supranuclear palsy (PSP) is the second most frequent cause of degenerative parkinsonism. In addition to... (601104) more...

MalaCards based summary: Supranuclear Palsy, Progressive, also known as progressive supranuclear palsy, is related to supranuclear palsy, progressive atypical and progressive supranuclear palsy-corticobasal syndrome, and has symptoms including frontal release signs, tremor and limb dystonia. An important gene associated with Supranuclear Palsy, Progressive is MAPT (Microtubule Associated Protein Tau), and among its related pathways are Neurotransmitter Clearance In The Synaptic Cleft and Acetylcholine Synthesis. Affiliated tissues include brain, eye and prefrontal cortex, and related mouse phenotypes are taste/olfaction and respiratory system.

UniProtKB/Swiss-Prot:69 Progressive supranuclear palsy 1: Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

MedlinePlus:37 Progressive supranuclear palsy (psp) is a rare brain disease. it affects brain cells that control the movement of your eyes. this leads to serious and permanent problems with balance and the way you walk. it usually occurs in middle-aged or elderly people. symptoms are very different in each person, but may include personality changes, speech, vision and swallowing problems. doctors sometimes confuse psp with parkinson's disease or alzheimer's disease. psp has no cure and no effective treatments. walking aids, special glasses and certain medicines might help somewhat. although the disease gets worse over time, it isn't fatal on its own. however, psp is dangerous because it increases your risk of pneumonia and choking from swallowing problems and injuries from falling. nih: national institute of neurological disorders and stroke

NINDS:48 Progressive supranuclear palsy (PSP) is a rare brain disorder that causes serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. One of the classic signs of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Some individuals describe this effect as a blurring. Affected individuals

Genetics Home Reference:25 Progressive supranuclear palsy is a brain disorder that affects movement, vision, speech, and thinking ability (cognition). The signs and symptoms of this disorder usually become apparent in mid- to late adulthood, most often in a person's 60s. Most people with progressive supranuclear palsy survive 5 to 9 years after the disease first appears, although a few affected individuals have lived for more than a decade.

Disease Ontology:11 A movement disease characterized by serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. It involves gradual deterioration and death of specific volumes of the brain.

NIH Rare Diseases:47 Progressive supranuclear palsy (PSP) is a degenerative neurologic disease due to damage to nerve cells in the brain. Signs and symptoms vary but may include loss of balance; blurring of vision; problems controlling eye movement; changes in mood, behavior and judgment; cognitive decline; and slowing and slurred speech. PSP is often misdiagnosed as Parkinson disease due to similar symptoms. Onset is usually after age 60 but may occur earlier. Most cases of PSP appear to be sporadic, but familial cases have been reported. Some cases have been found to be caused by a mutation in the MAPT gene, and other genetic factors are being studied. There is currently no effective treatment for PSP, and symptoms usually do not respond to medications. Research regarding potential treatments is ongoing. Last updated: 1/28/2016

Wikipedia:70 Progressive supranuclear palsy (PSP; or the Steele-Richardson-Olszewski syndrome, after the doctors who... more...

Related Diseases for Supranuclear Palsy, Progressive

About this section

Diseases in the Supranuclear Palsy, Progressive family:

Supranuclear Palsy, Progressive, 2 Supranuclear Palsy, Progressive, 3
Progressive Supranuclear Palsy, Mapt-Related

Diseases related to Supranuclear Palsy, Progressive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 72)
idRelated DiseaseScoreTop Affiliating Genes
1supranuclear palsy, progressive atypical12.2
2progressive supranuclear palsy-corticobasal syndrome12.2
3supranuclear palsy, progressive, 212.1
4supranuclear palsy, progressive, 312.1
5classic progressive supranuclear palsy syndrome12.1
6progressive supranuclear palsy-progressive non-fluent aphasia syndrome12.1
7pneumothorax, primary spontaneous11.5
8corticobasal degeneration11.1
9postinfectious vasculitis10.6APOE, MAPT
10angelman syndrome due to imprinting defect in 15q11-q1310.5LRRK2, SNCA
11epileptic hemiplegia10.3PARK2, SNCA
12basilar impression, primary10.3MAPT, RPS27A, SNCA
13suppurative thyroiditis10.3MAPT, SNCA
14hemiplegia alterans10.2APOE, CHAT, SNCA
15klippel-feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism10.2PARK2, PARK7, SNCA
16coenzyme q10 deficiency, primary, 110.2PARK2, PARK7, SNCA
17braddock jones superneau syndrome10.2SNCA, TH
18parkinson disease 6, early onset10.2LRRK2, PARK2, PARK7
19osteogenesis imperfecta, type i10.2CRHR1, MAPT
20atrial septal defect 910.1APP, MAPT, SNCA
21whiplash10.1LRRK2, MAPT, PARK2, SNCA
22parkinson disease 14, autosomal recessive10.1APP, RPS27A
23essential tremor10.1LRRK2, PARK2, SLC6A3, SNCA
24adrenocortical insufficiency, without ovarian defect10.1APP, MAPT
25parkinson disease 1010.0LRRK2, PARK2, PARK7, SNCA
26celiac disease 1210.0LRRK2, PARK2, PARK7, SNCA
27epilepsy, progressive myoclonic 1b10.0LRRK2, PARK2, PARK7, SNCA
28ovarian mucinous cystadenocarcinoma10.0SLC6A3, SNCA, TH
29symbrachydactyly of hands and feet10.0GRN, MAPT
30adult brain stem glioma10.0CBS, MAPT, SLC6A3, SNCA
31microsporidiosis10.0APOE, CBS, MAPT, SLC6A3
32hyperglycemia9.9GRN, SLC6A3
33gemistocytic astrocytoma9.9APOE, APP, MAPT, SNCA
34testicular seminoma9.9APOE, GRN, MAPT
35hypogonadism cardiomyopathy9.9ACHE, TH
36allergic bronchopulmonary aspergillosis, familial9.9APOE, APP, MAPT, RPS27A
37phka2-related phosphorylase kinase deficiency9.8LRRK2, MAPT, PARK2, PARK7, SNCA
38anaerobic pneumonia9.8APOE, APP, CHAT, MAPT
39andersen syndrome9.8GRN, MAPT, RPS27A
40cardiomyopathy, dilated, 1u9.8APOE, CHAT, MAPT, RPS27A, SNCA
41multiple system atrophy9.8
42cerebral atrophy9.8
43myoclonus9.8
44erythematosquamous dermatosis9.7ACHE, LRRK2, RPS27A, SLC6A3, SNCA
45west syndrome9.7ACHE, CHAT, TH
46siberian tick typhus9.7ACHE, CHAT
47gingival disease9.7CHAT, MAPT, RPS27A, TH
48nosophobia9.7APOE, GRN, LRRK2, MAPT
49retrograde amnesia9.7CBS, GRN, MAPT
50mucopolysaccharidosis iii9.7CHAT, GRN, MAPT

Graphical network of the top 20 diseases related to Supranuclear Palsy, Progressive:



Diseases related to supranuclear palsy, progressive

Symptoms for Supranuclear Palsy, Progressive

About this section

Symptoms by clinical synopsis from OMIM:

601104

Clinical features from OMIM:

601104

Human phenotypes related to Supranuclear Palsy, Progressive:

 63 53 (show all 43)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 frontal release signs63 45% HP:0000743
2 tremor63 53 30% Occasional (29-5%) HP:0001337
3 limb dystonia63 18% HP:0002451
4 supranuclear gaze palsy63 53 Very frequent (99-80%) HP:0000605
5 photophobia63 HP:0000613
6 blurred vision63 HP:0000622
7 diplopia63 HP:0000651
8 eyelid apraxia63 HP:0000658
9 irritability63 HP:0000737
10 apathy63 HP:0000741
11 dysarthria63 HP:0001260
12 parkinsonism63 HP:0001300
13 dysphagia63 53 Very frequent (99-80%) HP:0002015
14 rigidity63 53 Occasional (29-5%) HP:0002063
15 bradykinesia63 53 Frequent (79-30%) HP:0002067
16 gait imbalance63 HP:0002141
17 gliosis63 53 Frequent (79-30%) HP:0002171
18 neurofibrillary tangles63 HP:0002185
19 mutism63 HP:0002300
20 akinesia63 HP:0002304
21 memory impairment63 53 Frequent (79-30%) HP:0002354
22 frontolimbic dementia63 HP:0002439
23 falls63 53 Very frequent (99-80%) HP:0002527
24 granulovacuolar degeneration63 HP:0002528
25 neuronal loss in central nervous system63 53 Very frequent (99-80%) HP:0002529
26 axial dystonia63 HP:0002530
27 retrocollis63 HP:0002544
28 supranuclear ophthalmoplegia53 Very frequent (99-80%)
29 postural instability53 Very frequent (99-80%)
30 unsteady gait53 Very frequent (99-80%)
31 abnormal synaptic transmission53 Very frequent (99-80%)
32 impulsivity53 Very frequent (99-80%)
33 vertical supranuclear gaze palsy53 Frequent (79-30%)
34 slow saccadic eye movements53 Frequent (79-30%)
35 blepharospasm53 Frequent (79-30%)
36 depression53 Frequent (79-30%)
37 delayed speech and language development53 Frequent (79-30%)
38 dystonia53 Frequent (79-30%)
39 cerebral cortical atrophy53 Frequent (79-30%)
40 pseudobulbar signs53 Frequent (79-30%)
41 aphasia53 Frequent (79-30%)
42 cognitive impairment53 Frequent (79-30%)
43 dementia53 Occasional (29-5%)

UMLS symptoms related to Supranuclear Palsy, Progressive:


back pain, headache, muscle rigidity, ophthalmoplegia, pain, sciatica, seizures, syncope, tremor, apathy, photophobia, chronic pain, bradykinesia, blurred vision, mobility poor, vertigo/dizziness, forgetful, sleeplessness

Drugs & Therapeutics for Supranuclear Palsy, Progressive

About this section

Drugs for Supranuclear Palsy, Progressive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 92)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Rivastigmineapproved, investigationalPhase 3, Phase 283123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
2
Minocyclineapproved, investigationalPhase 322410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
3
Riluzoleapproved, investigationalPhase 3631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
4
RasagilineapprovedPhase 354136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
5Cholinesterase InhibitorsPhase 3, Phase 2570
6Protective AgentsPhase 3, Phase 2, Phase 17190
7Cholinergic AgentsPhase 3, Phase 23846
8Neuroprotective AgentsPhase 3, Phase 21672
9Neurotransmitter AgentsPhase 3, Phase 217734
10Trace ElementsPhase 2, Phase 3, Phase 15802
11MicronutrientsPhase 2, Phase 3, Phase 15802
12VitaminsPhase 2, Phase 3, Phase 15095
13Anti-Infective AgentsPhase 321402
14AnticonvulsantsPhase 3, Phase 22620
15Anti-Bacterial AgentsPhase 310884
16UbiquinonePhase 2, Phase 3139
17Excitatory Amino AcidsPhase 3, Phase 21297
18Excitatory Amino Acid AntagonistsPhase 3, Phase 21282
19
Coenzyme Q10experimental, NutraceuticalPhase 2, Phase 3114303-98-05281915
Synonyms:
(all-E)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-Cyclohexadiene-1,4-dione
(all-E)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-Cyclohexadiene-1,4-dione
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-Benzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-Cyclohexadiene-1,4-dione
4-Ethyl-5-fluoropyrimidine
Aqua Q 10L10
Aqua Q10
Bio-Quinon
Bio-Quinone Q10
CoQ10
Coenzyme Q-10
Coenzyme Q10
Ensorb
Kaneka Q10
 
Kudesan
Li-Q-Sorb
Liquid-Q
Neuquinon
Neuquinone
PureSorb Q 40
Q 10AA
Q-Gel
Q-Gel 100
Ubidecarenone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
Ubiquinone-10
Unbiquinone
Unispheres Q 10
20
DonepezilapprovedPhase 2280120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
21
Valproic Acidapproved, investigationalPhase 232299-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
22
DextromethorphanapprovedPhase 2129125-71-35360696, 5362449
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(-)-3-Methoxy-N-methylmorphinan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
32062-10-5
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
Balminil DM
Balminil DM Children
Bayer Select Flu Relief
Bayer Select Head & Chest Cold
Bayer Select Night Time Cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM (TN)
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
C06947
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
CID3008
CID5360696
CID5362449
Calmylin #1
Canfodion
Cerose-DM
Chloraseptic DM
Contac Day & Night Cold/Flu Day Caplets
Contac Jr. Non-drowsy Formula
Contac Nighttime Cold Medicine
Contac Severe Cold Formula Maximum Strength
Contac Severe Cold Formula Non-Drowsy
Coricidin Syrup
Cosylan
Cough-X
Creo-Terpin
D-Methorphan
D-Methorphan Hydrobromide
D-methorphan
D03742
DB00514
DEA No. 9210
DM
DXM
Delsym
Delsym Cough Formula
Delta-Methorphan
Demorphan
Demorphan Hydrobromide
Demorphan hydrobromide
Demorphine
Destrometerfano
Destrometerfano [DCIT]
Destrometerfano [Dcit]
Dex
Dextromethorfan
Dextromethorfan [Czech]
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan Bromhydrate
Dextromethorphan Bromide
Dextromethorphan [USP:INN:BAN]
Dextromethorphan hydrobromide OROS Tablets
Dextromethorphan hydrobromide [BAN:JAN]
Dextromethorphan hydrobromide monohydrate
Dextromethorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dextrométhorphane
Dexyromethorphan
Diabe-Tuss DM Syrup
 
Dimacol
Dimetapp DM
Dormetan
Dormethan
Drixoral Cough
Drixoral Cough & Congestion
Drixoral Cough & Sore Throat
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN Pediatric
HMS2090C08
HSDB 3056
Hihustan M.
Hold
Hold DM
Koffex DM
L-Methorphan
LS-91837
LS-91838
Levomethorphan
Levomethorphan [BAN:DCF:INN]
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
Lopac-D-2531
Lopac0_000337
MLS000758303
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Naldecon-DX
Novahistex DM
Novahistine DM
Ornex Severe Cold Formula
Orthoxicol
PediaCare 1
PediaCare Cough-Cold Formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Prestwick_686
RACEMETHORPHAN
Robitussin CF
Robitussin Cold & Cough
Robitussin Cough Calmers
Robitussin DM
Robitussin Maximum Strength Cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin Pediatric Cough
Robitussin Pediatric Cough & Cold
Robitussin Pediatric Cough Suppressant
Robitussin Pediatric Night Relief
Romilar
Rondec dm
Ru-Tuss Expectorant
SPBio_002378
St. Joseph Cough Syrup
Sucrets 4 Hour Cough Suppressant
Sudafed Cough Syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-Organidin
Tussi-Organidin DM NR
Tussi-Organidin DM-S NR
Tylenol Cold No Drowsiness
Tylenol Cold and Flu Multi-Symptom
Tylenol Cold and Flu No Drowsiness
Tylenol Cough + Decongestant Liquid
Tylenol Cough Liquid
Tylenol Flu No Drowsiness Gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
Viro-Med
d-Methorphan
delta-Methorphan
dextromethorphan
l-Methorphan
23
QuinidineapprovedPhase 24456-54-2441074
Synonyms:
(+)-quinidine
(-)-Quinine
(8R,9S)-Quinidine
(R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol
(S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol
(S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol
11010-73-4
12239-42-8
128544-03-6
130-89-2
130-95-0
1407-83-6
21480-31-9
22600_FLUKA
22620_FLUKA
22620_SIGMA
50-54-4
500225-45-6
549-56-4
55980-20-6
56-54-2
572-59-8
6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol
6119-70-6
6151-39-9
6151-40-2
6183-68-2
6591-63-5
6912-57-8
72646-90-3
767303-40-2
804-63-7
840482-04-4
845886-64-8
857212-53-4
864908-93-0
875538-34-4
882741-47-1
883881-01-4
888714-03-2
890027-24-4
894767-09-0
898813-59-7
898814-00-1
898814-28-3
899813-83-3
900786-66-5
900789-95-9
906550-97-8
909263-47-4
909767-48-2
909882-78-6
910878-25-0
910880-97-6
910899-51-3
911445-75-5
918778-04-8
AB00514657
AC1L199L
AC1L1ANE
AC1L1LHL
AC1L1R7Y
AC1L3RNZ
AC1L9AHT
AC1L9AHW
AC1LCUGN
AC1LDI43
AC1LDI46
AC1MBNAI
AC1MHDEF
AC1MHUCH
AC1MHWS7
AC1MI1Q5
AC1NSV55
AC1NSV58
AC1NSZYR
AC1NSZYU
AC1NUNML
AC1NUNMO
AC1NX8JM
AC1O56R7
AC1O7EE0
AC1O7GNZ
AC1OAH7Z
AC1OCD5W
AC1OCD62
AC1OFCPL
AC1Q4EZ5
AC1Q4EZ6
AC1Q58AF
AR-1A4833
AR-1H2065
Aflukin
Apo-Quinidine
Auriquin
BB_NC-0697
BIB1110
BIDD:GT0144
Biquin Durules
C06526
C06527
C20H24N2O2
CCRIS 5755
CCRIS 672
CHEBI:111177
CHEBI:15854
CHEBI:28593
CHEMBL170
CHEMBL21578
CHEMBL576997
CHEMBL601807
CHEMBL97
CID10448938
CID1065
CID25522
CID2728270
CID3000825
CID3032576
CID3034034
CID3036746
CID441073
CID441074
CID5317111
CID5317112
CID5320867
CID5320868
 
CID5484444
CID5484450
CID5748152
CID5953
CID637552
CID6453100
CID6602154
CID6604605
CID667448
CID667449
CID6857801
CID6916033
CID6916036
CID7048767
CID8549
CID94175
CID9967055
CIN-QUIN
CPD000857275
Cardioquin
Chinidin
Chinidine
Chinidinum
Chinin
Chinine
Cin-Quin
Coccinine
Coco-Quinine
Conchinin
Conchinine
Conquinine
D08458
D08460
DB00468
DB00908
Duraquin
Epiquinidine
FT-0082277
GNF-PF-5459
GNF-Pf-180
GNF-Pf-5423
HMS1304I22
HMS1607A11
HMS1989J09
HMS2089E05
HSDB 225
HSDB 2501
I14-3348
I14-3397
IBS-L0034250
IDI1_000134
KBio1_000134
KBio2_001392
KBio2_003960
KBio2_006528
KBio3_001551
KST-1A1085
Kinidin
Kinidin (TN)
L001278
LS-141252
LS-187236
LS-194958
LS-221
LS-4562
LT00645788
Lopac-Q-0875
Lopac-Q-1250
MLS001304041
MLS001335913
MLS001335914
NCI-C56246
NCI60_004320
NINDS_000134
NSC 192949
NSC 5362
NSC131458
NSC192949
NSC5362
NSC667852
Novoquinidin
OR28880
Pitayin
Pitayine
Q0006
Q3625_SIGMA
Quin-Release
Quinact
Quinaglute
Quinaglute Dura-Tabs
Quinalan
Quinate
Quinatime
Quindan
Quindine
Quinicardine
Quinidex
Quinidex Extentabs
Quinidina
Quinidine
Quinidine Gluconate
Quinidine Sulfate
Quiniduran
Quinimax
Quinine
Quinine Dab
Quinora
Quniacridine
RH01857
SAM002264644
SB01652
SMP1_000254
SMR000718748
SMR000857275
SPBio_001375
SPBio_002379
ST056282
TCMDC-131239
TNP00086
alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol
beta-Quinine
bmse000511
chinidinum
chininum
quinidina
quinidine
quinina
β-quinine
24
Guaifenesinapproved, vet_approvedPhase 261693-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
25AnestheticsPhase 1, Phase 29001
26Nootropic AgentsPhase 2, Phase 1701
27Pharmaceutical SolutionsPhase 1, Phase 27793
28GABA AgentsPhase 21622
29Antimanic AgentsPhase 2, Phase 1790
30RadiopharmaceuticalsPhase 2, Early Phase 1485
31Fluorodeoxyglucose F18Phase 2392
32Tranquilizing AgentsPhase 2, Phase 14164
33Psychotropic DrugsPhase 2, Phase 16279
34Central Nervous System DepressantsPhase 2, Phase 112806
35Antidepressive AgentsPhase 1, Phase 22666
36Lithium carbonatePhase 1, Phase 2232554-13-2
37Respiratory System AgentsPhase 24818
38Quinidine gluconatePhase 244
39Chlorpheniramine, phenylpropanolamine drug combinationPhase 2616
40Antitussive AgentsPhase 2520
41
Acetylcarnitineapproved, investigationalPhase 1443040-38-81
Synonyms:
(+-)-Acetylcarnitine
(-)-Acetylcarnitine
(R)-Acetylcarnitine
ALCAR
Acetyl-L-(-)-carnitine
Acetyl-L-carnitine
Acetyl-carnitine
Acetylcarnitine
 
L-Acetylcarnitine
L-Carnitine acetyl ester
L-O-Acetylcarnitine
Levocarnitine acetyl
Nicetile
O-Acetyl-L-carnitine
O-Acetylcarnitine
O-acetyl-L-carnitine
acetyl-L-carnitine
42
DopamineapprovedPhase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
43
Salicylic acidapproved, vet_approvedPhase 117569-72-7338
Synonyms:
105910_ALDRICH
105910_SIAL
2 Hydroxybenzoic Acid
2-Carboxyphenol
2-Hydroxybenzenecarboxylate
2-Hydroxybenzenecarboxylic acid
2-Hydroxybenzoate
2-Hydroxybenzoic acid
2-hydroxy(1-14c)benzoic acid
247588_SIAL
27301_SIAL
69-72-7
7681-06-3
8052-31-1
84210_FLUKA
84210_SIAL
AB1002436
AC1L190M
AC1Q1HCK
AC1Q72IF
AI3-02407
AKOS000118979
ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS)
AR-1E2203
ATA fraction 10, ammonium salt
Acid, 2-Hydroxybenzoic
Acid, Salicylic
Acid, o-Hydroxybenzoic
Acid, ortho-Hydroxybenzoic
Acido o-idrossibenzoico
Acido o-idrossibenzoico [Italian]
Acido salicilico
Acido salicilico [Italian]
Acidum salicylicum
Advanced Pain Relief Callus Removers
Advanced Pain Relief Corn Removers
Advanced pain relief callus removers
Advanced pain relief corn removers
Akurza Cream
Akurza Lotion
Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid)
BENZOIC ACID,2-HYDROXY SALICYLIC ACID
BIDD:ER0602
BRN 0774890
Benzoic acid, 2-hydroxy- (9CI)
C00805
CCRIS 6714
CHEBI:16914
CHEMBL424
CID338
CMC_13852
Caswell No. 731
Clear away Wart Remover
Clear away wart remover
Compound W
Compound w
D00097
D020156
DB00936
DHS Sal Shampoo
DivK1c_000301
Domerine
Dr. Scholl'S Callus Removers
Dr. Scholl'S Corn Removers
Dr. Scholl'S Wart Remover Kit
Dr. Scholl's callus removers
Dr. Scholl's corn removers
Dr. Scholl's wart remover kit
DuoPlant Gel
Duofil Wart Remover
Duofil wart remover
Duofilm
Duoplant
E9A559BE-383B-4F83-BC02-3031D03D558A
EINECS 200-712-3
EPA Pesticide Chemical Code 076602
Freezone
H0206
HSDB 672
Hydrisalic Gel
I04-0192
IDI1_000301
InChI=1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10
Ionil
Ionil Plus
Ionil plus
Ionil-Plus
 
K 537
K 557
KBio1_000301
KBio2_001428
KBio2_003996
KBio2_006564
KBioSS_001428
Keralyt
Kyselina 2-hydroxybenzoova
Kyselina 2-hydroxybenzoova [Czech]
Kyselina salicylova
Kyselina salicylova [Czech]
LS-2169
MLS000069653
Mediplast pads
MolPort-001-769-476
NCGC00159447-02
NCGC00159447-04
NINDS_000301
NSC 180
NSC180
NSC629474
O-Carboxyphenol
O-Hydroxybenzoate
O-Hydroxybenzoic acid
O-carboxyphenol
O-hydroxybenzoic acid
Occlusal
Oprea1_040343
Orthohydroxybenzoic acid
P&S Shampoo
Phenol-2-carboxylate
Phenol-2-carboxylic acid
Propa pH Peel-Off Acne Mask
Psoriacid-S-Stift
Psoriacid-S-stift
Retarder SAX
Retarder W
Rutranex
S5922_SIGMA
S7401_SIGMA
S8519_SIGMA
SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS)
SALICYLIC ACID, ACS
SAX
SBB052826
SGCUT00012
SMP2_000145
SMR000059163
STK258681
Salex Cream
Salex Lotion
Salicyclic acid
Salicylate
Salicylic acid
Salicylic acid & Sulfur Soap
Salicylic acid (6CI,8CI)
Salicylic acid (JP15/USP)
Salicylic acid (TN)
Salicylic acid Soap
Salicylic acid [USAN:JAN]
Salicylic acid collodion
Salicylic acid soap
Salicylic acid, tech
Salicylic acid, tech.
Salicylic acid-ring-UL-14C
Saligel
Salonil
Sebucare
Sebulex
Spectrum_000948
Stri-Dex
Trans-Ver-Sal
UNII-O414PZ4LPZ
UPCMLD-DP126
UPCMLD-DP126:001
Verrugon
W398500_ALDRICH
WLN: QVR BQ
bmse000252
o Hydroxybenzoic Acid
o-Carboxyphenol
o-hydroxybenzoic acid
ortho Hydroxybenzoic Acid
ortho-Hydroxybenzoic Acid
phenol derivative, 7
salicylate
salicylic acid
to_000004
44
Benzoic AcidapprovedPhase 1765-85-0243
Synonyms:
Benzenecarboxylate
Benzenecarboxylic acid
Benzeneformate
Benzeneformic acid
Benzenemethanoate
Benzenemethanoic acid
Benzenemethonic acid
Benzoate
Benzoic acid
Benzoic acid sodium salt
 
Carboxybenzene
Diacylate
Diacylic acid
Dracylate
Dracylic acid
Oracylic acid
Phenylcarboxylate
Phenylcarboxylic acid
Phenylformate
Phenylformic acid
Sodium benzoate
Sodium benzoic acid
45
Folic Acidapproved, nutraceutical, vet_approvedPhase 1427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
46
Niacinapproved, investigational, nutraceuticalPhase 190659-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Nicacid
Nicamin
Nicangin
 
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
47Pyruvateapproved, NutraceuticalPhase 138
48
Creatineapproved, nutraceuticalPhase 112657-00-1586
Synonyms:
((amino(Imino)methyl)(methyl)amino)acetic acid
((amino(imino)methyl)(methyl)amino)acetate
((amino(imino)methyl)(methyl)amino)acetic acid
(N-methylcarbamimidamido)acetic acid
(alpha-Methylguanido)acetate
(alpha-Methylguanido)acetic acid
(α-methylguanido)acetic acid
Cosmocair C 100
Creatin
Creatine
Creatine hydrate
Kreatin
 
Krebiozon
Methylglycocyamine
Methylguanidoacetate
Methylguanidoacetic acid
N-(Aminoiminomethyl)-N-Methyl-Glycine
N-(aminoiminomethyl)-N-methylglycine
N-Amidinosarcosine
N-Carbamimidoyl-N-methylglycine
N-Methyl-N-guanylglycine
N-[(e)-AMINO(imino)methyl]-N-methylglycine
Phosphagen
[[Amino(imino)methyl](methyl)amino]acetate
[[Amino(imino)methyl](methyl)amino]acetic acid
alpha-Methylguanidino acetic acid
49
Nicotinamideapproved, NutraceuticalPhase 190298-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3 amide
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
50AntioxidantsPhase 12928

Interventional clinical trials:

(show top 50)    (show all 73)
idNameStatusNCT IDPhase
1Validation of DaTscan for Detection of Parkinson Disease Related DisordersUnknown statusNCT02138682Phase 4
2Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyCompletedNCT01110720Phase 2, Phase 3
3Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)CompletedNCT00382824Phase 2, Phase 3
4Effects of Coenzyme Q10 in PSP and CBDCompletedNCT00532571Phase 2, Phase 3
5Study About Efficacy and Safety to Treat Multi-System-AtrophyCompletedNCT00146809Phase 3
6Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyRecruitingNCT02839642Phase 3
7Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyTerminatedNCT01187888Phase 3
8Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)TerminatedNCT00211224Phase 3
9Study of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsyUnknown statusNCT00139373Phase 2
10Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of ParkinsonismUnknown statusNCT01824121Phase 1, Phase 2
11Efficacy Study for Treatment of Dementia in Progressive Supranuclear PalsyUnknown statusNCT00522015Phase 2
12Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)CompletedNCT00385710Phase 2
13Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyCompletedNCT00328874Phase 2
14A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationCompletedNCT00703677Phase 1, Phase 2
15Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear PalsyCompletedNCT00005903Phase 2
16The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission TomographyCompletedNCT01824056Phase 2
17A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyRecruitingNCT02985879Phase 2
18Safety, Tolerability and Efficacy of AVP-786 for the Treatment of DisinhibitionRecruitingNCT02534038Phase 2
19Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyActive, not recruitingNCT01056965Phase 2
20Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear PalsyUnknown statusNCT01537549Phase 1
21Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy VolunteersCompletedNCT02167594Phase 1
22A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.CompletedNCT00605930Phase 1
23Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsCompletedNCT02103894Phase 1
24Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and MoodCompletedNCT02104401Phase 1
25Young Plasma Transfusions for Progressive Supranuclear PalsyRecruitingNCT02460731Phase 1
26A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyRecruitingNCT02422485Phase 1
27Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyActive, not recruitingNCT02494024Phase 1
28Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyActive, not recruitingNCT02460094Phase 1
29Safety Study of TPI-287 to Treat CBS and PSPActive, not recruitingNCT02133846Phase 1
30Extension Study of BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in CN002003Enrolling by invitationNCT02658916Phase 1
31Postural Instability in Progressive Supranuclear PalsyUnknown statusNCT01563276
32Robot Walking Rehabilitation in Parkinson's DiseaseUnknown statusNCT01668407
33Diagnostic and Prognostic Biomarkers in Parkinson DiseaseUnknown statusNCT00653783
34Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and PersonalizedUnknown statusNCT01403519
35Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian SyndromesUnknown statusNCT00368199Early Phase 1
36Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyCompletedNCT01049399
37Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear PalsyCompletedNCT02734485
38Rehabilitation in Patients With Progressive Supranuclear PalsyCompletedNCT02109393
39Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and ControlsCompletedNCT01348061
40Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal DegenerationCompletedNCT01174771
41Risk Factors for Progressive Supranuclear Palsy (PSP)CompletedNCT00431301
422-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismCompletedNCT02214862Early Phase 1
43Analysis of the Enteric Nervous System Using Colonic BiopsiesCompletedNCT01353183
44Prefrontal Cortex and Abstract ThinkingCompletedNCT01100281
45Research of Biomarkers in Parkinson DiseaseCompletedNCT00465790Early Phase 1
46Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesCompletedNCT02531360Early Phase 1
47Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance ImagingCompletedNCT01715727
48Study of Tongue PressuresCompletedNCT00013832
49Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's DiseaseCompletedNCT02243982Early Phase 1
50Diagnosis and Natural History Study of Patients With Neurological ConditionsCompletedNCT00001549

Search NIH Clinical Center for Supranuclear Palsy, Progressive


Cochrane evidence based reviews: supranuclear palsy, progressive

Genetic Tests for Supranuclear Palsy, Progressive

About this section

Genetic tests related to Supranuclear Palsy, Progressive:

id Genetic test Affiliating Genes
1 Progressive Supranuclear Ophthalmoplegia26

Anatomical Context for Supranuclear Palsy, Progressive

About this section

MalaCards organs/tissues related to Supranuclear Palsy, Progressive:

35
Brain, Eye, Prefrontal cortex, Tongue, Colon, Cortex, Bone

Animal Models for Supranuclear Palsy, Progressive or affiliated genes

About this section

MGI Mouse Phenotypes related to Supranuclear Palsy, Progressive:

40 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539410.2APOE, MAPT, SLC6A3, SNCA
2MP:00053889.0ACHE, APOE, CRHR1, LRRK2, PARK2, TH
3MP:00053698.8ACHE, APOE, APP, CHAT, MAPT, PARK2
4MP:00053858.7APOE, CHAT, CRHR1, LRRK2, MAPT, PARK2
5MP:00107718.6APOE, APP, LRRK2, MAPT, PARK2, SLC6A3
6MP:00028738.4APP, CHAT, CRHR1, LRRK2, MAPT, SLC6A3
7MP:00053898.3ACHE, APOE, APP, CHAT, GRN, SLC6A3
8MP:00053787.6ACHE, APOE, APP, CHAT, MAPT, PARK2
9MP:00053847.4APOE, APP, GRN, LRRK2, MAPT, PARK2
10MP:00053917.4ACHE, APOE, CHAT, CRHR1, GRN, MAPT
11MP:00030127.2ACHE, APOE, APP, CRHR1, GRN, LRRK2
12MP:00107686.6ACHE, APOE, APP, CHAT, CRHR1, GRN
13MP:00053866.2ACHE, APOE, APP, CHAT, CRHR1, GRN
14MP:00053766.2ACHE, APOE, APP, CHAT, CRHR1, GRN
15MP:00036316.2ACHE, APOE, APP, CHAT, CRHR1, GRN

Publications for Supranuclear Palsy, Progressive

About this section

Variations for Supranuclear Palsy, Progressive

About this section

UniProtKB/Swiss-Prot genetic disease variations for Supranuclear Palsy, Progressive:

69
id Symbol AA change Variation ID SNP ID
1MAPTp.Arg5LeuVAR_019661rs63750959
2MAPTp.Gly620ValVAR_037439rs63751391

Clinvar genetic disease variations for Supranuclear Palsy, Progressive:

5
id Gene Variation Type Significance SNP ID Assembly Location
1MAPTNM_016835.4(MAPT): c.1853C> T (p.Pro618Leu)SNVPathogenicrs63751273GRCh37Chr 17, 44087755: 44087755
2MAPTNM_016835.4(MAPT): c.14G> T (p.Arg5Leu)SNVPathogenicrs63750959GRCh37Chr 17, 44039717: 44039717
3MAPTNM_016835.4(MAPT): c.2006C> T (p.Ser669Leu)SNVPathogenicrs63750425GRCh37Chr 17, 44096041: 44096041
4MAPTNM_016835.4(MAPT): c.1859G> T (p.Gly620Val)SNVPathogenicrs63751391GRCh37Chr 17, 44087761: 44087761

Expression for genes affiliated with Supranuclear Palsy, Progressive

About this section
Search GEO for disease gene expression data for Supranuclear Palsy, Progressive.

Pathways for genes affiliated with Supranuclear Palsy, Progressive

About this section

Pathways related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 12)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8ACHE, SLC6A3
29.6ACHE, CHAT
39.5APOE, APP, MAPT
49.5APOE, APP, MAPT
5
Show member pathways
9.3PARK2, PARK7, SLC6A3, SNCA
6
Show member pathways
9.1ACHE, SLC6A3, TH
7
Show member pathways
9.0ACHE, CHAT, TH
89.0ACHE, CHAT, TH
98.7PARK2, PARK7, SLC6A3, SNCA, TH
10
Show member pathways
8.4LRRK2, PARK2, PARK7, SLC6A3, SNCA, TH
118.4LRRK2, PARK2, PARK7, SLC6A3, SNCA, TH
127.6APOE, APP, LRRK2, MAPT, PARK2, PARK7

GO Terms for genes affiliated with Supranuclear Palsy, Progressive

About this section

Cellular components related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1inclusion bodyGO:001623410.7LRRK2, SNCA
2postsynapseGO:009879410.4LRRK2, SNCA
3smooth endoplasmic reticulumGO:00057909.9APP, TH
4synaptic vesicleGO:00080219.8LRRK2, SNCA, TH
5presynapseGO:00987939.7CHAT, PARK2, PARK7, SLC6A3
6growth coneGO:00304269.4APP, LRRK2, MAPT, SNCA
7neuronal cell bodyGO:00430259.4APOE, LRRK2, SLC6A3, TH
8membrane raftGO:00451219.4APP, LRRK2, PARK7, SLC6A3
9terminal boutonGO:00431959.2APP, LRRK2, SNCA, TH
10dendriteGO:00304259.1APOE, LRRK2, MAPT, TH
11perinuclear region of cytoplasmGO:00484719.0ACHE, APP, PARK2, PARK7, SNCA
12Golgi apparatusGO:00057948.8ACHE, APOE, APP, LRRK2, PARK2, SNCA
13synapseGO:00452028.4ACHE, APP, GRN, LRRK2, SNCA
14neuron projectionGO:00430058.1APP, CHAT, LRRK2, PARK2, PARK7, SLC6A3
15extracellular spaceGO:00056157.8ACHE, APOE, APP, GRN, LRRK2, RPS27A
16axonGO:00304247.6APP, LRRK2, MAPT, PARK7, SLC6A3, SNCA
17plasma membraneGO:00058867.2ACHE, APOE, APP, CRHR1, LRRK2, MAPT
18cytoplasmGO:00057376.1APOE, APP, CBS, CHAT, LRRK2, MAPT
19cytosolGO:00058296.0APP, CBS, CHAT, GRN, LRRK2, MAPT

Biological processes related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 39)
idNameGO IDScoreTop Affiliating Genes
1regulation of synaptic vesicle transportGO:190280310.5LRRK2, PARK2
2virion assemblyGO:001906810.5APOE, RPS27A
3regulation of neuronal synaptic plasticityGO:004816810.5APOE, SNCA
4negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayGO:190337710.5PARK2, PARK7
5negative regulation of hydrogen peroxide-induced cell deathGO:190320610.4LRRK2, PARK7
6regulation of neurotransmitter secretionGO:004692810.4PARK2, SNCA
7negative regulation of oxidative stress-induced cell deathGO:190320210.4PARK2, PARK7
8axo-dendritic transportGO:000808810.4APP, MAPT
9regulation of neuron deathGO:190121410.4LRRK2, SNCA
10regulation of canonical Wnt signaling pathwayGO:006082810.4LRRK2, PARK2
11regulation of reactive oxygen species metabolic processGO:200037710.4PARK2, SNCA
12cellular response to dopamineGO:190335110.3LRRK2, PARK2
13protein localization to mitochondrionGO:007058510.3LRRK2, PARK2
14regulation of dopamine metabolic processGO:004205310.2PARK2, SLC6A3
15phosphatidylcholine biosynthetic processGO:000665610.2ACHE, CHAT
16regulation of dopamine secretionGO:001405910.1PARK2, SNCA
17regulation of autophagyGO:001050610.0LRRK2, MAPT, PARK2
18cellular response to oxidative stressGO:003459910.0LRRK2, PARK7, SNCA
19negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayGO:190223610.0LRRK2, PARK2, PARK7
20regulation of locomotionGO:004001210.0LRRK2, SNCA
21dopamine uptake involved in synaptic transmissionGO:00515839.9PARK2, PARK7, SLC6A3, SNCA
22positive regulation of dendritic spine developmentGO:00609999.9APOE, GRN
23mitochondrion organizationGO:00070059.9LRRK2, PARK2, PARK7
24synaptic vesicle endocytosisGO:00484889.9GRN, SNCA
25cellular response to manganese ionGO:00712879.9LRRK2, PARK2, TH
26dopamine metabolic processGO:00424179.8PARK2, SNCA
27dopamine biosynthetic processGO:00424169.8SLC6A3, SNCA, TH
28negative regulation of protein phosphorylationGO:00019339.7LRRK2, PARK2, PARK7, SNCA
29mating behaviorGO:00076179.6APP, TH
30negative regulation of neuron apoptotic processGO:00435249.6APOE, PARK2, PARK7, SNCA
31neurotransmitter biosynthetic processGO:00421369.6ACHE, SLC6A3, TH
32response to oxidative stressGO:00069799.5APOE, APP, LRRK2, PARK2
33cellular protein metabolic processGO:00442679.5APP, PARK2, RPS27A, SNCA
34negative regulation of neuron deathGO:19012159.5APOE, LRRK2, PARK2, PARK7, SNCA
35adult locomotory behaviorGO:00083449.4APP, PARK2, PARK7, SNCA
36response to ethanolGO:00454719.2CHAT, SLC6A3, TH
37synaptic transmission, dopaminergicGO:00019639.0PARK2, PARK7, SNCA, TH
38response to drugGO:00424938.6CHAT, PARK7, SLC6A3, SNCA, TH
39locomotory behaviorGO:00076268.5APP, PARK2, SLC6A3, TH

Molecular functions related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1tau protein bindingGO:004815610.7APOE, SNCA
2lipoprotein particle bindingGO:007181310.7APOE, MAPT
3phospholipase bindingGO:004327410.5PARK2, SNCA
4ubiquitin-specific protease bindingGO:199038110.4PARK2, PARK7
5ferrous iron bindingGO:000819810.2SNCA, TH
6dopamine bindingGO:00352409.6SLC6A3, TH
7protein homodimerization activityGO:00428038.6ACHE, APOE, CBS, LRRK2, PARK7
8identical protein bindingGO:00428028.1APOE, APP, CBS, LRRK2, PARK2, PARK7
9enzyme bindingGO:00198998.0APP, CBS, MAPT, PARK2, PARK7, SNCA
10protein bindingGO:00055154.6ACHE, APOE, APP, CBS, CRHR1, GRN

Sources for Supranuclear Palsy, Progressive

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet